On Thursday, it was shared by Sanofi-Aventis and CureDM Group Holding LLC that they are working on a diabetes treatment and are trying to make the patient’s body to produce insulin and other pancreatic hormones.

This research would be costing the biotechnology company CureDM, more than $35 million.

The treatment being followed currently focuses on the adding up of insulin to the body or helping the diabetes patients to control the insulin that their bodies already make.

It has seen in the preclinical studies that the drug known as Pancreate stimulates the growth of new insulin making islets in the body. It helps the patient make the metabolic function normal and control glucose in the blood.

Worldwide license has been given to Sanofi-Aventis to develop, make and sell the medicine known as Pancreate. The payment would be received by CureDM along with development, regulatory and commercial milestone payments. The payments given to them would be $335 million.

"About 40 to 60 percent are destroyed in Type II diabetes patients at diagnosis, and almost 80 percent are destroyed in Type I patients at diagnosis. CureDM sees that islet destruction as the root cause of diabetes. Everything flows from there", said CureDM CEO, H. Joseph Reiser.